Evidence map›Paper›PMID 41169352›Full record

ReviewFrontiers in synaptic neuroscience2025

Is it possible to prevent excessive synaptic pruning in schizophrenia? Possibilities and limitations.

Agnieszka Pawlak, Jakub Stefanowicz, Zofia Kotkowska, Agata Gabryelska, Marcin Sochal, Filip Napieraj, Magdalena Kotlicka-Antczak, Dominik Strzelecki

Abstract readReview
In one paragraph

Review in Frontiers in synaptic neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Agnieszka PawlakDepartment of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, Poland.
Jakub StefanowiczDepartment of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, Poland.
Zofia KotkowskaDepartment of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, Poland.
Agata GabryelskaDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Łódź, Łódź, Poland.
Marcin SochalDepartment of Sleep Medicine and Metabolic Disorders, Medical University of Łódź, Łódź, Poland.
Filip NapierajMedical University of Warsaw, Warsaw, Poland.
Magdalena Kotlicka-AntczakDepartment of Child and Adolescent Psychiatry, Medical University of Łódź, Łódź, Poland.
Dominik StrzeleckiDepartment of Affective and Psychotic Disorders, Medical University of Łódź, Łódź, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Synaptic pruning is a critical neurodevelopmental process that eliminates redundant or weak synaptic connections to optimize brain circuitry. In schizophrenia, converging evidence from imaging, genetic, and postmortem studies suggests that this process is pathologically accelerated, particularly in the prefrontal cortex during adolescence. The resulting reduction in synaptic density has been implicated in disrupted neural connectivity observed in psychosis, with the onset of cognitive impairment and negative symptoms. Objective: This review explores whether modulating aberrant synaptic pruning could serve as a preventive or early intervention strategy for schizophrenia. We analyze domains with emerging therapeutic relevance: tetracycline antibiotics, the complement system and C4 gene, kynurenine pathway modulation, epigenetic therapies, neuroprotective strategies (e.g., BDNF, NF-κB, progranulin), genetic and transcriptional regulators of pruning, and other new, mostly hypothetical, options. We also discuss the limitations of the impact on pruning. Methods: We conducted a structured review of the mechanisms involved in pruning, as well as clinical trials, preclinical studies, and mechanistic models that investigate molecular targets influencing synaptic pruning in schizophrenia. Results: Several molecular pathways have been implicated in abnormal synaptic pruning in schizophrenia, including complement C4A overexpression, kynurenine pathway imbalance (KYNA/QUIN), and dysregulation of microglial and transcriptional modulators such as MEF2C and TCF4. While retrospective studies suggest minocycline or doxycycline may reduce psychosis risk, randomized trials remain inconclusive. Emerging interventions, including LSD1 inhibitors, BDNF/progranulin enhancers, and lifestyle-based epigenetic modulation, show promise but require further validation in clinical settings. We also discuss the limitations of these methods, including safety considerations. Conclusion: Targeted modulation of synaptic pruning represents a promising but complex therapeutic strategy. The timing, specificity, and reversibility of interventions are crucial to avoid disrupting essential neurodevelopment. Future efforts should focus on identifying biomarkers for patient stratification and validating preventive strategies in high-risk populations.

Indexed as

BDNFC4Akynurenine pathwaymicroglianeuroprotectionpsychosis preventionschizophreniasynaptic pruning

Identifiers

PMID41169352
PMCPMC12568506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.